Oruka Therapeutics, Inc. ORKA Conversion Of Series A Nonvoting Convertible Preferred Stock To Common Stock
Conversion Of Series A Nonvoting Convertible Preferred Stock To Common Stock at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept orka:ConversionOfSeriesANonvotingConvertiblePreferredStockToCommonStock.
The official record: Oruka Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s conversion of series a nonvoting convertible preferred stock to common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s conversion of series a nonvoting convertible preferred stock to common stock?
- Oruka Therapeutics, Inc. (ORKA) reported conversion of series a nonvoting convertible preferred stock to common stock of $52.83M in Q4 2024.
- What does conversion of series a nonvoting convertible preferred stock to common stock mean?
- The non-cash value associated with the conversion of preferred equity instruments into common stock. This metric tracks the simplification of the capital structure as preferred shares are retired and replaced by common equity.